OncoMatch/Clinical Trials/NCT07315750

A Study of Disitamab Vedotin Combined With Trastuzumab and Tislelizumab Versus Chemotherapy Combined With Trastuzumab With or Without Pembrolizumab in HER2-high Expression Advanced Gastric or Gastroesophageal Junction Adenocarcinoma.

Is NCT07315750 recruiting? Yes, currently enrolling (May 2026). This Phase 3 trial studies multiple treatments for gastric carcinoma.

Phase 3RecruitingRemeGen Co., Ltd.NCT07315750Data as of May 2026

Treatment: Disitamab Vedotin · Tislelizumab · CAPOX (oxaliplatin/capecitabine) · Trastuzumab · Pembrolizumab — The purpose of this study is to evaluate the efficacy and safety of Disitamab Vedotin combined with Trastuzumab and Tislelizumab Versus Chemotherapy Combined with Trastuzumab with or without Pembrolizumab as First-Line Treatment for Advanced Gastric/Gastroesophageal Junction Adenocarcinoma with HER2-high Expression.

Check if I qualify

Extracted eligibility criteria

Cancer type

Gastric Cancer

Biomarker criteria

Required: HER2 (ERBB2) high expression (high)

Performance status

ECOG 0–1(Restricted strenuous activity)

Prior therapy

No prior treatment (treatment-naive required)

Max 0 prior lines

Lab requirements

Blood counts

adequate organ function

Kidney function

adequate organ function

Liver function

adequate organ function

Adequate organ function

Structured fields extracted by AI. May contain errors — verify against the official protocol.

Could you qualify for this trial?

Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.

Check if I qualify